Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02289014
Other study ID # KFS-3260-08-2013
Secondary ID
Status Completed
Phase N/A
First received October 9, 2014
Last updated May 5, 2017
Start date January 2014
Est. completion date March 2017

Study information

Verified date May 2017
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many cancer patients experience their illness as substantial psychological burden. About half of the cancer patients suffer from severe stress symptoms and around one third of the patients fulfill the criteria for a clinically relevant psychological disorder (mainly anxiety disorder and/or major depression). Studies show, that a high level of distress in cancer patients is associated with more side effects of and a reduced compliance for oncological treatment.

Today, the efficacy of psycho-oncological interventions is well studied and proven. Besides the reduction of levels of anxiety, distress and depression, psycho-oncological support facilitates dealing with physical complaints and increases quality of life. Yet, psycho-oncological support is rarely utilized by male patients and insufficiently accessible for many patients (i.a. lack of supply in the respective area, cost issues).

The internet overcomes some of these barriers, as it can be used independently of time and location. Internet-based therapies are therefore a growing field of interest in research and there is evidence for treatment efficacy for several psychological disorders. Moreover effect sizes of traditional face-to-face and interactive web-based interventions are comparable. However, web-based interventions for cancer patients are still scarce. The present research project therefore develops a comprehensive stress management program accessible for a vast number of cancer patients. The study targets primarily to evaluate the feasibility of the program (technical, organizational feasibility, accessibility). In addition, the preliminary efficacy of the program will be analyzed in order to adapt future programs for specific patient groups.


Description:

The present study is designed as a randomized controlled wait-list intervention study. Within 12 weeks of the start of anti-cancer treatment, patients will be randomly assigned to the web-based stress management intervention or a wait-list control condition.

Inclusion criteria:

Patients with any kind of newly diagnosed cancer undergoing first Treatment regardless of the Setting. Patients undergoing first treatment for newly diagnosed relapse of cancer, who have received prior curatively-intended Treatment.

Inclusion is allowed immediately prior to or within 12 weeks of the start of treatment. If surgery was performed initially and is followed by systemic treatment or radiotherapy, start of systemic treatment or radiotherapy is counted as first treatment. Prior treatment -including chemotherapy- for a different, prior malignant tumor is allowed. Concomitant participation in an experimental therapeutic drug trial is allowed. Age >18 years. Command of the German language. Internet access and basic computer skills. Life expectancy of >6 months.

Exclusion criteria:

Patients undergoing second- or further line treatment. Patients treated with surgery only. Patients participating in a concomitant psychological intervention trial


Recruitment information / eligibility

Status Completed
Enrollment 129
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with any kind of newly diagnosed cancer undergoing first treatment (including radiotherapy, hormonal treatment, targeted therapies, chemotherapy or combined-modality treatment) regardless of the setting (adjuvant treatment, curative treatment, palliative first-line treatment)

- Patients with newly diagnosed relapse of cancer, who had received prior curatively-intended treatment

- Inclusion is allowed immediately prior to or within 12 weeks of the start of treatment

- Patients must have cytologically or histologically proven diagnosis of malignant disease (either at diagnosis or at relapse)

- Prior treatment -including chemotherapy- for a different, prior malignant tumor is allowed

- Concomitant participation in an experimental therapeutic drug trial is allowed

- Age >18 years

- Command of the German language

- Internet access and basic computer skills

- Life expectancy of >6 months

Exclusion Criteria:

- Patients undergoing palliative second- or further line chemotherapy treatment

- Patients treated with surgery only

- Patients participating in a concomitant psychological intervention trial

Study Design


Related Conditions & MeSH terms


Intervention

Other:
online stress Management program
Active treatment group

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland Swiss Cancer Research, Swiss National Science Foundation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dropout rate during the internet-based recruitment procedure Measures assessed at time point of recruitment
Primary Characteristics (Sociodemographic and medical history; i.e. age, gender, education, cancer diagnosis and cancer treatment) of the population willing to participate in an online stress management program shortly after diagnosis of cancer Measures assessed at time point of recruitment
Primary Number of participants who completed at least 6 out of 8 modules, i.e. 75 % of each module participants will be followed for the duration of the intervention, an expected average of 8 weeks
Primary Working Alliance scores on the Working Alliance (WAI) Questionnaire participants will be followed for the duration of the intervention, an expected average of 8 weeks
Primary Usability scores on the System Usability Scale (SUS) participants will be followed for the duration of the intervention, an expected average of 8 weeks
Primary Client satisfaction on the Client Satisfaction Questionnaire-8 (CSQ-8) German Version of the Client Satisfaction Questionnaire: Fragebogen zur Messung der Patientenzufriedenheit (ZUF-8) will be used Measures assessed after 8 weeks
Secondary Psychological distress on the Distress Thermometer (visual analogue scale) Change measures (e.g., "baseline, 8 weeks")
Secondary Anxiety and Depression scores on the Hospital Anxiety and Depression Scale (HADS) Change measures (e.g., "baseline, 8 weeks")
Secondary Quality of life and fatigue scores on the Functional Assessment in Cancer Therapy-Fatigue (FACT-F) hange measures (e.g., "baseline, 8 weeks")
Secondary Avoidance and psychological inflexibility scores on the Acceptance and Action questionnaire (AAQ) German Version of the Acceptance and Action questionnaire: Fragebogen zur Akzeptanz und Handeln (FAH II) will be used ange measures (e.g., "baseline, 8 weeks")
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients